---
title: "Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292284837.md"
description: "Cytokinetics, Incorporated's average 12-month price target has been raised to $108.47 by 19 analysts, up from $107.80. This revision implies a 26% upside based on the July 9 closing price. The consensus rating remains 'Buy' across 22 covering analysts, with 20 buys, 2 holds, and no sells."
datetime: "2026-07-10T07:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292284837.md)
  - [en](https://longbridge.com/en/news/292284837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292284837.md)
generator: "portal-rs"
---

# Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside

-   According to estimates from 19 analysts, Cytokinetics, Incorporated stock's average price target has risen from $107.8 to $108.47, with forecasts ranging from $83 to $146 per share
-   Based on the Jul. 9 closing price, the updated target implies approximately 26% potential upside
-   Consensus rating remains at “Buy” across 22 covering analysts, with 20 Buys, 2 Holds and 0 Sells

Explore more price target data and ratings for Cytokinetics, Incorporated on the , and track all previous and future analyst recommendations for Cytokinetics, Incorporated in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $265,370](https://longbridge.com/en/news/296267986.md)
- [Top Cytokinetics Executive Makes Attention-Grabbing Move With Insider Stock Sale](https://longbridge.com/en/news/296290252.md)
- [Cytokinetics grants new-hire equity awards, stock options priced at $74.13 per share](https://longbridge.com/en/news/296264145.md)
- [Does Interparfums’ (IPAR) Earnings Upgrade Hint At Deeper Strength In Its Profit Model?](https://longbridge.com/en/news/296564505.md)
- [Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative](https://longbridge.com/en/news/296006872.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**